Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 23707171)

1.

Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines.

Izurieta HS, Zuber P, Bonhoeffer J, Chen RT, Sankohg O, Laserson KF, Sturkenboom M, Loucq C, Weibel D, Dodd C, Black S.

Vaccine. 2013 Aug 2;31(35):3623-7. doi: 10.1016/j.vaccine.2013.05.027. Epub 2013 May 21.

PMID:
23707171
2.
3.

A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program.

Baker MA, Lieu TA, Li L, Hua W, Qiang Y, Kawai AT, Fireman BH, Martin DB, Nguyen MD.

Am J Epidemiol. 2015 Apr 15;181(8):608-18. doi: 10.1093/aje/kwu322. Epub 2015 Mar 13.

PMID:
25769306
4.

Post-licensure monitoring to evaluate vaccine safety.

de St Maurice A, Edwards KM.

J Pediatr. 2015 Mar;166(3):513-5. doi: 10.1016/j.jpeds.2014.12.031. No abstract available.

PMID:
25722262
5.

The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.

Lopalco PL, DeStefano F.

Vaccine. 2015 Mar 24;33(13):1541-8. doi: 10.1016/j.vaccine.2014.10.047. Epub 2014 Nov 4. Review.

6.

The Global Vaccine Safety Initiative: enhancing vaccine pharmacovigilance capacity at country level.

Maure CG, Dodoo AN, Bonhoeffer J, Zuber PL.

Bull World Health Organ. 2014 Sep 1;92(9):695-6. doi: 10.2471/BLT.14.138875. Epub 2014 Jul 31. No abstract available.

7.

China enters the global vaccine market.

Parry J.

Bull World Health Organ. 2014 Sep 1;92(9):626-7. doi: 10.2471/BLT.14.020914.

8.

Vaccines against poverty.

MacLennan CA, Saul A.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12307-12. doi: 10.1073/pnas.1400473111. Epub 2014 Aug 18.

9.

Vaccines: can transparency increase confidence and reduce hesitancy?

Byington CL.

Pediatrics. 2014 Aug;134(2):377-9. doi: 10.1542/peds.2014-1494. Epub 2014 Jul 1. No abstract available.

10.

Ranking Vaccines: A Prioritization Software Tool: Phase II: Prototype of a Decision-Support System.

Committee on Identifying and Prioritizing New Preventive Vaccines for Development, Phase II, Board on Population Health and Public Health Practice, Board on Global Health, Institute of Medicine; Madhavan G, Sangha K, Phelps C, Fryback D, Rappuoli R, Martinez RM, King L, editors.

Washington (DC): National Academies Press (US); 2013 Oct 17.

11.

The immune space: a concept and template for rationalizing vaccine development.

Manrique A, Adams E, Barouch DH, Fast P, Graham BS, Kim JH, Kublin JG, McCluskey M, Pantaleo G, Robinson HL, Russell N, Snow W, Johnston MI.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1017-22. doi: 10.1089/AID.2014.0040. Epub 2014 Jun 26.

12.

Infections and possible vaccine-drug interactions.

Raaska K, Neuvonen PJ.

Eur J Clin Pharmacol. 2014 Jul;70(7):889-90. doi: 10.1007/s00228-014-1688-8. Epub 2014 May 8. No abstract available.

PMID:
24801149
13.

Protection against vaccine-preventable diseases in medical students: a follow up.

Urwyler P, Dierig A, Walther K, Heininger U.

Pediatr Infect Dis J. 2014 Oct;33(10):1057-9. doi: 10.1097/INF.0000000000000381.

PMID:
24776519
14.

Editorial overview: Vaccines: Vaccines for infectious diseases: are we there yet?

Khader SA, Kolls JK.

Curr Opin Immunol. 2014 Jun;28:ix-x. doi: 10.1016/j.coi.2014.03.005. Epub 2014 Apr 12. No abstract available.

PMID:
24735901
15.

The impact of vaccines on public health: the role of ESCMID.

Poljak M, Norrby R.

Clin Microbiol Infect. 2014 May;20 Suppl 5:1. doi: 10.1111/1469-0691.12598. No abstract available.

PMID:
24698089
16.

[Self-controlled case-series (SCCS) method as a tool for the evaluation on the safety of vaccine].

Pan JR, He HQ, Yan R, Fu J.

Zhonghua Liu Xing Bing Xue Za Zhi. 2013 Aug;34(8):836-9. Chinese.

PMID:
24423775
17.

Introducing new vaccines in developing countries.

Kochhar S, Rath B, Seeber LD, Rundblad G, Khamesipour A, Ali M; Vienna Vaccine Safety Initiative.

Expert Rev Vaccines. 2013 Dec;12(12):1465-78. doi: 10.1586/14760584.2013.855612. Review.

PMID:
24195483
18.

TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.

Clark A, Jauregui B, Griffiths U, Janusz CB, BolaƱos-Sierra B, Hajjeh R, Andrus JK, Sanderson C.

Vaccine. 2013 Jul 2;31 Suppl 3:C19-29. doi: 10.1016/j.vaccine.2013.05.045.

PMID:
23777686
19.

Systematic documentation of new vaccine introduction in selected countries of the Latin American Region.

de Oliveira LH, Toscano CM, Sanwogou NJ, Ruiz-Matus C, Tambini G, Roses-Periago M, Andrus JK.

Vaccine. 2013 Jul 2;31 Suppl 3:C114-22. doi: 10.1016/j.vaccine.2013.05.032. Review.

PMID:
23777684
20.

Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants.

Griffiths UK, Clark A, Hajjeh R.

J Pediatr. 2013 Jul;163(1 Suppl):S50-S59.e9. doi: 10.1016/j.jpeds.2013.03.031.

PMID:
23773595
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk